Strengthening manufacturing functions for regenerative medicine products

「In August 2026, Cell Resources株式会社 began operations at the 羽田Process Development Center (羽田PDC), a development and manufacturing site for regenerative medicine. The company established a framework for process development, quality testing, investigational product manufacturing and support for regulatory approval, and will work to strengthen development and manufacturing functions within regenerative medicine TSCS.」

「From the beginning of the current interim consolidated accounting period, we newly included Cell Resources株式会社, our wholly owned subsidiary engaged in the regenerative medicine business and headquartered in Chiyoda Ward, Tokyo, as a consolidated subsidiary. We are focusing on manufacturing and storing master cells and developing the CMO and CDMO businesses, while working to establish a framework for launching each project at an early stage.」

「In April 2024, セルリソーシズ株式会社, a wholly owned subsidiary of the Company (head office: Chiyoda-ku, Tokyo), entered into an agreement with the National Center for Child Health and Development, an independent administrative agency, for the supply of commercially usable human (allogeneic) somatic stem cell materials.」

「Cell Resources Co., Ltd., which became a wholly owned subsidiary of the Company through an organizational reorganization, entered into a bioindustry support agreement with Miltenyi Biotec B.V. & Co. KG (head office: Federal Republic of Germany) in July 2023 to support the design, construction and operation of automated cell manufacturing facilities and processes in the gene and cell therapy market.」

「As part of an organizational restructuring effective 1 April 2023, the company established the Group Medical Wholesale Business Oversight Department, the Total Supply Chain Services Planning and Promotion Department, the Regenerative Medicine Business Planning and Development Office and the Distribution Compliance Office, among other changes」

「Through a CPC (cell culture and processing facility) for allogeneic cells constructed in Koriyama, Fukushima Prefecture, the company aims to provide a stable supply of high-quality master cells to pharmaceutical companies engaged in drug discovery and others. It also handles autologous cells at the CPC in Kawasaki-ku, Kawasaki, acquired through a business transfer, thereby strengthening its manufacturing capabilities in regenerative medicine for both autologous and allogeneic cells.」

「In addition, our consolidated subsidiary アルフレッサ株式会社 established セルリソーシズ株式会社 to contribute to the stable supply of regenerative medicine products. Through a cell culture and processing facility for allogeneic cells under construction in Koriyama, Fukushima Prefecture, the company aims to provide a stable supply of high-quality master cells to pharmaceutical companies engaged in drug discovery and others. It also handles autologous cells at the cell processing centre in Kawasaki-ku, Kawasaki, acquired through a business transfer, thereby strengthening its manufacturing capabilities in regenerative medicine for both autologous and allogeneic cells.」